“FDA registered” is not “FDA approved”: how to read FDA records on stem cell and exosome products

Establishment registration

• Who creates it: The establishment, electronically (§ 1271.22). Each registered location receives a registration number (§ 1271.27(a)), and registration is updated each December (§ 1271.21(b)).
• What it shows: That the establishment filed its legal name, locations and reporting official with FDA’s Center for Biologics Evaluation and Research, and the status shown in the public query.
• What it does not show: Compliance with the rules, a licence or an approval (§ 1271.27(b)).
• How to check: Search the Human Cell and Tissue Establishment Registration public query by establishment name, function, product, status or location. Status can be registered, inactive or pre-registered; note which one applies and match the legal name and location to the claim.

HCT/P listing

• Who creates it: The same establishment, as part of its registration (§ 1271.25(b)).
• What it shows: Which HCT/Ps the establishment says it handles, and whether it states that each one meets the § 1271.10 criteria, such as minimal manipulation and homologous use.
• What it does not show: That FDA agrees with that statement. An HCT/P that does not meet the criteria, and qualifies for no exception, is regulated as a drug, device and/or biological product (§ 1271.20).
• How to check: The same public query, searched by product.

Investigational New Drug application (IND)

• Who creates it: A clinical study sponsor. FDA’s IND page describes it as “a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.”
• What it shows: That a sponsor has sought FDA authorisation to use an investigational product in a study.
• What it does not show: A licence to market the product. FDA’s BLA page describes IND-stage studies as collecting safety and efficacy information for a later licence application.
• How to check: FDA’s 2019 notification on exosome products suggests asking the clinical investigator for the FDA-issued IND number and the FDA communication acknowledging the IND before treatment. Under 21 CFR 312.40(b), FDA notifies the sponsor of the date it received an IND and the IND takes effect later, so acknowledgment of receipt alone does not establish permission to proceed; ask for the relevant FDA correspondence. An NCT number is a separate registry identifier: see clinical trial registration versus approval.

Biologics licence (BLA approval)

• Who creates it: The applicant, through a Biologics License Application: in FDA’s words, the submission “through which an applicant requests permission to introduce a biological product into interstate commerce.”
• What it shows: If FDA finds that the data adequately demonstrate the product’s safety, effectiveness and quality, and that the facility meets the required standards, it issues a US licence to market that product. The licence belongs to a named product, manufacturer and indication.
• What it does not show: Anything about a different product, even one made from a similar kind of cell, or about a use outside the licensed indication.
• How to check: The product page reached from FDA’s approved-products list, described next.

The approved cellular and gene therapy products list

• Who creates it: FDA. The list introduces itself as “a list of licensed products from the Office of Therapeutic Products (OTP).” On 17 October 2026 it carried a content-current date of 17 September 2026.
• What it shows: Each licensed product by trade name and proper name, with its manufacturer and a link to a product page. The RYONCIL page, for example, states the indication and links the approval documents.
• What it does not show: A register of every product FDA regulates. Absence from this list is not a finding about a product, and presence covers only the product and indication named.
• How to check: Find the exact trade name and proper name, open the product page, and compare its indication with the claim.

Warning letters

• Who creates it: FDA. Its explanation of warning letters says: “When FDA identifies what it believes are significant violation(s) of federal requirement(s), FDA notifies the appropriate party. This notification is often in the form of a Warning Letter.”
• What it shows: The concerns FDA stated, to whom and on what date. The letter asks for a response, and the recipient may address the concerns or supply its own reasoning.
• What it does not show: Current compliance by itself; subsequent FDA correspondence may change the status of the issues. FDA may issue a close-out letter after it has verified corrective actions, usually by a follow-up inspection.
• How to check: Enter the company name from the claim in FDA’s warning-letter search. Results show the posted and issue dates, issuing office and subject, and can be filtered for response or close-out letters. Read the letter itself: the body describes the products and claims at issue.

Consumer alerts and safety notifications

• Who creates it: FDA, for the public. These pages state FDA’s general position; they are not product records.
• What it shows: FDA’s view on the date of the page. The 2019 Public Safety Notification on Exosome Products states: “There are currently no FDA-approved exosome products.” It also states that, as a general matter, exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products subject to premarket review and approval requirements. The consumer alert on regenerative medicine products repeats the exosome statement.
• What it does not show: The status of a particular product or firm, or anything that changed after the page date.
• How to check: Compare the page’s “Content current as of” date with the current product record.

Does “FDA registered” mean a stem cell product is approved?

No. FDA states that a firm having registered with FDA and listed its product does not mean the product is legally marketed. For HCT/P filings under 21 CFR Part 1271, § 1271.27(b) adds that FDA acceptance is not a determination of compliance, licensure or approval.

What does an FDA warning letter about an exosome or stem cell product establish?

It records the concerns FDA stated to a named recipient on a given date and asks for a response. It does not show current compliance by itself: subsequent FDA correspondence may change the status of the issues, and a close-out letter may follow once FDA has verified corrections. Finding no letter does not establish compliance either.

Does an FDA registration say anything about a clinic in Korea?

Not about treatment in Korea. Foreign HCT/P establishments may have US registration obligations, depending on their activities and applicable exceptions. Registration does not establish authorisation for treatment in Korea. FDA states that it does not have oversight of treatments done in other countries, so Korean status needs Korean records.